Volume | 662,849 |
|
|||||
News | - | ||||||
Day High | 0.5339 | Low High |
|||||
Day Low | 0.503 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Sangamo Therapeutics Inc | SGMO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.52 | 0.503 | 0.5339 | 0.5178 | 0.503 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
2,989 | 662,849 | US$ 0.517706 | US$ 343,161 | - | 0.2911 - 1.78 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:44:37 | formt | 200 | US$ 0.5101 | USD |
Sangamo Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
93.03M | 178.91M | - | 176.23M | -257.83M | -1.44 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sangamo Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SGMO Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.4787 | 0.57 | 0.46001 | 0.5100533 | 1,335,856 | 0.0314 | 6.56% |
1 Month | 0.6702 | 0.6938 | 0.46001 | 0.5467464 | 1,553,769 | -0.1601 | -23.89% |
3 Months | 0.5195 | 1.48 | 0.46001 | 0.8489052 | 2,484,752 | -0.0094 | -1.81% |
6 Months | 0.474 | 1.48 | 0.2911 | 0.6729121 | 2,031,531 | 0.0361 | 7.62% |
1 Year | 1.61 | 1.78 | 0.2911 | 0.8628762 | 2,072,449 | -1.10 | -68.32% |
3 Years | 11.80 | 12.8297 | 0.2911 | 3.61 | 1,625,858 | -11.29 | -95.68% |
5 Years | 11.85 | 19.43 | 0.2911 | 6.55 | 1,694,283 | -11.34 | -95.70% |
Sangamo Therapeutics Description
Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies. |